1. Home
  2. EVG vs NKTX Comparison

EVG vs NKTX Comparison

Compare EVG & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVG
  • NKTX
  • Stock Information
  • Founded
  • EVG 2005
  • NKTX 2015
  • Country
  • EVG United States
  • NKTX United States
  • Employees
  • EVG N/A
  • NKTX N/A
  • Industry
  • EVG Investment Managers
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVG Finance
  • NKTX Health Care
  • Exchange
  • EVG Nasdaq
  • NKTX Nasdaq
  • Market Cap
  • EVG 149.9M
  • NKTX 170.8M
  • IPO Year
  • EVG N/A
  • NKTX 2020
  • Fundamental
  • Price
  • EVG $11.19
  • NKTX $2.05
  • Analyst Decision
  • EVG
  • NKTX Strong Buy
  • Analyst Count
  • EVG 0
  • NKTX 5
  • Target Price
  • EVG N/A
  • NKTX $15.20
  • AVG Volume (30 Days)
  • EVG 49.4K
  • NKTX 853.6K
  • Earning Date
  • EVG 01-01-0001
  • NKTX 03-20-2025
  • Dividend Yield
  • EVG 8.68%
  • NKTX N/A
  • EPS Growth
  • EVG N/A
  • NKTX N/A
  • EPS
  • EVG N/A
  • NKTX N/A
  • Revenue
  • EVG N/A
  • NKTX N/A
  • Revenue This Year
  • EVG N/A
  • NKTX N/A
  • Revenue Next Year
  • EVG N/A
  • NKTX N/A
  • P/E Ratio
  • EVG N/A
  • NKTX N/A
  • Revenue Growth
  • EVG N/A
  • NKTX N/A
  • 52 Week Low
  • EVG $9.13
  • NKTX $1.96
  • 52 Week High
  • EVG $10.86
  • NKTX $16.24
  • Technical
  • Relative Strength Index (RSI)
  • EVG 54.97
  • NKTX 39.74
  • Support Level
  • EVG $11.14
  • NKTX $1.96
  • Resistance Level
  • EVG $11.27
  • NKTX $2.35
  • Average True Range (ATR)
  • EVG 0.10
  • NKTX 0.15
  • MACD
  • EVG -0.01
  • NKTX -0.00
  • Stochastic Oscillator
  • EVG 55.56
  • NKTX 19.15

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

About NKTX Nkarta Inc.

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Share on Social Networks: